Aditxt, Inc.

Equities

ADTX

US0070256047

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-03 EDT			5-day change	1st Jan Change
1.99 ^USD	+3.65%		-1.97%	-69.98%

05-24	Aditxt, Inc. announced that it has received $0.775 million in funding	CI
05-20	Aditxt, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Aditx Therapeutics, Inc. Appoints Thomas J. Farley as Principal Accounting Officer

March 24, 2021 at 05:24 pm

On March 19, 2021, the board of directors of Aditx Therapeutics, Inc. appointed Thomas J. Farley as Principal Accounting Officer of the Company. Mr. Farley currently serves as the Controller of the Company. Since October 2020, Mr. Farley has been the Controller on the Company.

Latest news about Aditxt, Inc.

Aditxt, Inc. announced that it has received $0.775 million in funding	05-23	CI
Aditxt, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Aditxt, Inc. announced that it has received $0.075135 million in funding	05-19	CI
Aditxt, Inc. announced that it expects to receive $4.2 million in funding	05-02	CI
Aditxt, Inc. announced that it expects to receive $150 million in funding	05-01	CI
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Appili Therapeutics To be Acquired by Aditxt, Inc.	04-02	MT
Aditxt, Inc. announced that it has received $6.000003 million in funding	01-03	CI
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data	01-02	MT
Top Premarket Decliners	01-02	MT
Aditxt, Inc. announced that it expects to receive $6.000003 million in funding	12-28	CI
Sector Update: Health Care Stocks Advance Late Afternoon	12-12	MT
Top Midday Gainers	12-12	MT
Top Premarket Gainers	11-30	MT
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Aditxt, Inc. Announces Board Changes	11-09	CI
Aditxt Closes $10 Million Private Placement	23-09-07	MT
Aditxt, Inc. announced that it has received $10 million in funding	23-09-05	CI
Top Premarket Decliners	23-09-05	MT
Top Premarket Decliners	23-09-01	MT
Aditxt Prices $10 Million Private Placement of Common Shares	23-09-01	MT
Aditxt, Inc. announced that it expects to receive $10 million in funding	23-08-30	CI
Aditxt, Inc. Enters into Business Loan and Security Agreement	23-08-28	CI
Top Premarket Decliners	23-08-21	MT
Aditxt to Implement 1-for-40 Reverse Stock Split	23-08-17	MT

Chart Aditxt, Inc.

Duration

Period

More charts

Company Profile

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADITXT, INC.	-69.98%	3.31M
VERTEX PHARMACEUTICALS INCORPORATED	+15.55%	121B
REGENERON PHARMACEUTICALS, INC.	+12.66%	107B
BIONTECH SE	-2.53%	24.82B
ARGENX SE	+0.99%	22.48B
GENMAB A/S	-9.54%	18.32B
WUXI APPTEC CO., LTD.	-42.28%	16.33B
BEIGENE, LTD.	-18.92%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+6.19%	14.08B
SAREPTA THERAPEUTICS, INC.	+28.83%	11.74B

Bio Therapeutic Drugs